Full title

Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use

Running title

Quality control program for the manufacture of mesenchymal stem cells

Authors

PATRICIA GALVEZ¹, BEATRIZ CLARES², MARIA BERMEJO¹, ABDELKRAM HMADCHA¹,³,* and BERNAT SORIA¹,³,*

Affiliations

¹ Department of Stem Cells, Andalusian Center for Molecular Biology and Regenerative Medicine (CABIMER), Cartuja-93 Scientific and Technological Park, Americo Vespucio Ave s/n, 41092, Seville, Spain.

² Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Campus of Cartuja, 18071, University of Granada, Spain.

³ Centre for Network Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Bosanova Street 69, 6th floor, 08017 Barcelona, Spain

*These authors share the senior authorship

Correspondence: Patricia Gálvez Martín, Abdelkrim Hmadcha and Bernat Soria, Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER) Avenida América Vespucio s/n 41092, Sevilla, Spain Tel.: +34 954 468004 Fax: +34 954 461664 E-mails: patricia.galvez@cabimer.es; karim.hmadcha@cabimer.es and bernat.soria@cabimer.es
Abstract

**Background:** The manufacturing of human mesenchymal stem cells (hMSCs) as cell-based products for clinical use should be performed with appropriate controls that ensure its safety and quality. The use of hMSCs in cell therapy has increased considerably in the past few years. In line with this, the assessment and management of contamination risks by microbial agents that could affect the quality of cells and the safety of patients have to be considered. It is necessary to implant a quality control program (QCP) covering the entire procedure of the *ex vivo* expansion, from the source of cells, starting materials and reagents, such as intermediate products to the final cellular medicine.

**Methods:** We defined a QCP to detect microbiological contamination during manufacturing of autologous hMSCs for clinical application. The methods used include, sterility test, Gram stain, detection of mycoplasma, endotoxin assay and microbiological monitoring in process according to the European Pharmacopoeia (Ph. Eur.) and each analytical technique was validated in accordance with three different cell cultures.

**Results:** Results showed no microbiological contamination in any phases of the cultures, meeting all the acceptance criteria for sterility test, detection of mycoplasma and endotoxin, environmental and staff monitoring. Each analytical technique was validated demonstrating the sensitivity, limit of detection and robustness of the method.

**Discussion:** The quality and safety of MSCs must be controlled to ensure their final use in patients. The evaluation of the proposed QCP revealed satisfactory results in order to standardize this procedure for clinical use of cells.

**Key Words:** cell therapy, endotoxin, mesenchymal stem cell, mycoplasma, quality control, sterility, validation
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BET</td>
<td>Bacterial Endotoxin Test</td>
</tr>
<tr>
<td>CTMP</td>
<td>Cell-based Therapy Medical Product</td>
</tr>
<tr>
<td>CFU</td>
<td>Colony Forming Unit</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s Modified Eagle’s Medium</td>
</tr>
<tr>
<td>EL</td>
<td>Endotoxin Limit</td>
</tr>
<tr>
<td>EU</td>
<td>Endotoxin Unit</td>
</tr>
<tr>
<td>EDQM</td>
<td>European Directorate for the Quality of Medicines</td>
</tr>
<tr>
<td>Ph. Eur.</td>
<td>European Pharmacopoeia</td>
</tr>
<tr>
<td>FBS</td>
<td>Fetal Bovine Serum</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practice</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>hMSCs</td>
<td>Human Mesenchymal Stem Cells</td>
</tr>
<tr>
<td>IgM</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonization</td>
</tr>
<tr>
<td>λ</td>
<td>Labelled Lysate Sensitivity</td>
</tr>
<tr>
<td>LOD</td>
<td>Limit of Detection</td>
</tr>
<tr>
<td>LAL</td>
<td>Limulus Amebocyte Lysate</td>
</tr>
<tr>
<td>MCB</td>
<td>Master Cell Bank</td>
</tr>
<tr>
<td>MVD</td>
<td>Maximum Valid Dilution</td>
</tr>
<tr>
<td>NAT</td>
<td>Nucleic Acid Amplification Technique</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>QCP</td>
<td>Quality Control Program</td>
</tr>
<tr>
<td>SDC</td>
<td>Sabouraud Dextrosa Cloramfenicol</td>
</tr>
<tr>
<td>TPB</td>
<td>Thioglycollate Penase Broth</td>
</tr>
<tr>
<td>TSA</td>
<td>Trycase Soja Agar</td>
</tr>
<tr>
<td>TSPB</td>
<td>Tryptic Soy Penase Broth</td>
</tr>
<tr>
<td>WCB</td>
<td>Working Cell Bank</td>
</tr>
</tbody>
</table>
Introduction

Cell-based therapy has led to the development of new biological medicines to repair, replace or recover the biological function of damaged tissues and organs (1). Among cell types used for this propose, hMSC are considered as Cell-based Therapy Medical Product (CTMP) and should be handled with appropriate controls to ensure their safety, quality and efficacy as a final medicine (8), (9).

The manufacture of hMSCs involves an ex vivo expansion for a relatively long period of time, which leads to a risk of contamination by microbiological agents that could affect the quality and safety of the cells (10). Contamination of a CTMP can cause adverse reactions in patients (e.g. fever, chills, infections, irreversible septic shock) and even death (10, 11). Therefore it will be necessary to standardize and validate all procedures and analytical techniques involved in the manufacture of CTMP (12), posing a Quality Control Program (QCP).

A QCP should ensure that cells have been manufactured in aseptic conditions, under GMP conditions to minimize the contamination risk of the cell medicine and thus, to ensure the safety of patients and the quality of the medicine. This program will comprise the whole process of ex vivo expansion, starting from type of cells, source of materials, reagents and intermediate products, to CTMP, the final cellular medicine (13-14). Chiefly, because the cells must be viable for their administration and should not be sterilized by physico-chemical methods, in this in this scenario a risk analysis must be performed to determine the posibilities of microbiological contamination before designing a QCP. For a QCP applied to a CTMP, each analytical technique should be justified, and the amount and type of evidence required for microbiological quality control defined according to the different pharmacopoeias, as well as, the guidelines issued by regulatory agencies and International Conference on Harmonisation (ICH) in
particular Quality guidelines (15, 16). Validation studies must be performed for each analytical technique to demonstrate and verify that the procedure adopted at each site laboratory does not alter the method and consequently the result (17).

The aim of this study was to develop a microbial QCP of a CTMP (Figure 1), for the long-term expansion of human adipose derived MSCs. In particular, the manufactured medicine was an injectable cell suspension, elaborated by suspending the active principle (hMSCs) and other additives (culture medium or packing medium), packaged in a suitable container to be administered parenterally (intramuscular, intravenous, intra-arterial). Contamination by bacteria, fungi, mycoplasma and bacterial endotoxin concentration were analyzed in line with QCP proposed in different phases such as Master Cell Bank (MCB), Working Cell Bank (WCB) and in the final cellular medicine. Each analytical technique was validated by three different cell cultures process.

**Materials and Methods**

This study was performed in the quality control unit of the CABIMER’s GMP facility authorized by the Spanish Agency of Medicines and Medical Devices and regularly inspected by the Spanish competent authorities.

1. **Isolation and culture of hMSCs**

Autologous hMSCs were isolated from abdobiminal adipose tissue biopsies of patients enrolled in a Phase I/II clinical trial. All donors provided informed consent that was formerly approved by local and regional medical research ethics committees. Each patient was appropriately screened and tested for human pathogens. In particular, the presence of Human Immunodeficiency Virus (HIV), hepatitis B and hepatitis C virus were analyzed. On the other hand, all starting materials and reagents required for the
expansion were analyzed to certify that they were sterile and endotoxin-free.

Cells were isolated from human adipose tissue by enzymatic digestion with collagenase (2 mg collagenase/1 g adipose tissue) (Roche Farma, Reinach, BL, Switzerland), centrifuged at 400 g for 10 min, filtered and washed with Phosphate Buffered Saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA) to obtain the stromal cells. These cells were suspended and plated at medium density of $12-20 \times 10^4$ cells/cm$^2$ in culture flasks (Nunc, Roskilde, Roskilde-DK4 000, Denmark) with expansion medium composed by Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 10% Fetal Bovine Serum (FBS), 1% of 10,000 IU/mL Penicillin, 10 mg/mL Streptomycin, 2% of 200 mM L-alanine solution and 1% of 200 mM L-glutamina, (all Sigma-Aldrich, St. Louis, MO, USA). After 24 hours, non-adherent cells were removed by replacing the expansion medium. The medium was replaced every 2 or 3 days a week. Cells were harvested upon reaching 80% confluence, and subcultured using 0.25% trypsin (Gibco, Invitrogen, Grand Island, NY, USA) in expansion medium, and plated at medium density, 3500–5500 cells/cm$^2$. Cells were cultured under 95% relative humidity, at 37 °C and 5% CO$_2$. Three different processes of *ex vivo* expansion hMSCs were carried out (named: 1, 2 and 3) from passages 3-4 to analyze their microbiological quality. For the final product, cells were packed at concentration of $1 \times 10^6$ cells/mL with 1 mL of packaging medium composed by 50% of Glucose 5%, 45% of Lactated Ringer’s solution and 55% of Albumin 20% (Grifols, Barcelona, Spain). hMSCs were packed in 10mL Luer-lock syringes (Becton Dickinson and Company, Franklin Lakes, NJ, USA).

2. **Sterility test and Gram stain**

The test was carried out in different phases (MCB, WCB and final cellular medicine), by direct inoculation of 1 mL of intermediate product (supernatant) or final suspension
in the microbiology medium, so that volume of the product is not more than 10 per cent of the volume of the medium but not less than 1 ml (18). Two media were used: Thioglycollate Penase Broth 125 mL (TPB) (BDH Prolabo, Mexico D.F., Mexico), to detect anaerobic and aerobic bacteria, and Tryptic Soy Penase Broth 125 mL (TSPB) (BDH Prolabo, Mexico D.F., Mexico), which is a soybean casein digest medium to detect fungi and aerobic bacteria. For each media (TPB and TSPB), both sterility test and growth promotion test of aerobes, anaerobes and fungi were verified before testing, the strains used in the growth promotion test are indicated in the Table I. A negative control was included inoculating 1 mL of 0.9% sterile NaCl (bioMérieux, Marcy l'Etoile, France) for each medium. The inoculated media were incubated for 14 days at 35 ºC and 22 ºC for TPB and TSPB, respectively. If microbial growth appears after 14 days, the medium will show turbidity.

Sterility test was performed as soon as possible after sample collection, which was stored at 5 ± 3 ºC for up to 24 hours (19) to avoid phagocytosis of microorganisms by cells present in the sample. This assay was performed in aseptic conditions with an isolator HPI-4PI-S (Esco Technologies, Inc., Hatboro, PA, USA).

Additionally, in each final cellular medicine for the three cultures, the presence/absence of colony forming unit (cfu) was examined by standard procedure of Gram staining (20). Spanish Agency of Medicines and Medical Devices recommends that Gram staining should be performed before releasing the medicine to verify that there is no contamination. If the Gram stain is positive, the cells will not be administered.

Picture of Gram stains were taken using bright field microscope (Zeiss Axioskop 40, Carl Zeiss Mediatec AG, Jena, Germany). The stains were photographed by a microscope Zeiss Axioskop 40 (Carl Zeiss Mediatec AG, Jena, Germany), data not shown.
3. Detection of mycoplasma

The test was carried out in different phases (MCB, WCB and final cellular medicine), cells are centrifuged and resuspended in $\ldots\ldots\mu$L/mL? the expansion medium and the detection of mycoplasma in the final cellular medicine was as previously described (21). In order to perform this assay, $5 \times 10^5$ cells in 500 $\mu$L of supernatant were used. Briefly, the sample was introduced in the dry block thermostat (TDB-120, Biosan Ltd., Riga, Latvia) to inactivate DNAses at 95 ºC for 10 min to avoid mycoplasma DNA degradation. Then, genomic DNA extraction was performed by the method of MB DNA (Minerva Biolabs, Berlin, Germany), which is sensitive for mycoplasma genomes. DNA was amplified by the Nucleic Acid Amplification Technique (NAT) with a PCR Mycoplasma detection kit (VenorGeM, Minerva Biolabs, Berlin, Germany). The DNA polymerase used for the amplification was MB Taq DNA polymerase (Minerva Biolabs, Berlin, Germany). The PCR device utilized was a Life Express thermal cycler (Bioer Technology Co., Hangzhou, P. R. China). The amplification products were analyzed by gel electrophoresis in the FlashGel® DNA System containing ethidium bromide (Lonza, Walkersville, MD, USA). The bands of any PCR amplicons were visualized by UV translumination. They were identified by comparing them with the bands visible in the positive control and the negative control reaction. The presence of mycoplasma was indicated by an amplification product at approximately 267 bp. A 191 bp band in every lane was indicated a successfully performed PCR without polymerase inhibition. The samples were analyzed before to 24 h after their collection, which after inactivation were stored for 6 days from 2 ºC to 8 ºC (22).

4. Endotoxin assay
The bacterial endotoxin test method (BET) was used to detect the endotoxin unit (EU) by the Gel-Clot technique Limulus Amebocyte Lysate (LAL) (Pyrogent Ultra Lonza, Walkersville, MD, USA) (23, 24) from the sample in different phases (MCB, WCB and final cellular medicine). For the endotoxin assay in the final cellular medicine, cells are centrifuged and the resulting pellet is resuspended in µL/mL? the expansion medium. 1/10 dilution of sample was necessary (100 µL of sample in 900 µL of water for BET), this dilution did not exceed the Maximum Valid Dilution (MVD). Then, 100 µL of LAL and 100 µL of the diluted sample were mixed in a pyrogen-free tube (Lonza, Walkersville, MD, USA). Each sample also included a negative control (100 µL of LAL and 100 µL water for BET), and two different positive controls (100 µL of LAL and 100 µL of 2λ/diluted test solution or 2λ/ water for BET). Each dilution was assayed in duplicate. All tubes were incubated at 37 ºC for 1 h in a water bath (Grant Instruments Ltd., Cambridge, UK). Each tube was examined to observe the presence/absence of gelation. The storage conditions of the samples in this assay are not defined, so each laboratory should define and validate those conditions.

4.1. Storage stability testing

To determine sample storage conditions, a study was performed using a purified standard control of endotoxin from Escherichia coli (ATCC 12014) 10 ng/vial with a potency of 4 EU/ng (Lonza, Walkersville, MD, USA). The samples were prepared adding 200 µL of standard control and 1800 µL of sample obtaining a solution of 0.8 EU/mL. 2 mL solution was stored at 4 ºC and −20 ºC for 6 months in duplicate, and analyzed at different times (24 h, 48 h, 7 days, 14 days, 28 days, 2 months, 3 months, 4 months, 5 months and 6 months). For each assay the storage sample was vigorously vortexed for 15 min. Then 100 µL of stored sample were mixed with 900 µL of water
for BET obtaining a dilution 1:10. Equally, a negative control was evaluated in each assay.

5. Microbiological monitoring in process

An environmental microbiological monitoring plan was carried out to control the air, surfaces and staff in accordance with the European Union standards: EudraLex - Volume 4 GMP guidelines. The environmental and staff monitoring were conducted during the manufacturing process and the sterility assay in work areas (laminar flow cabin and isolator, respectively) with settle plates. Two media were used, Trypcase Soja Agar (TSA) (bioMérieux, Marcy l'Etoile, France) for detection of bacteria and Sabouraud Dextrose Chloramphenicol (SDC) (bioMérieux, Marcy l'Etoile, France) for fungi. The plates were incubated for 2 days at 35 ºC for TSA and 5 days at 22 ºC for SDC (25).

For environmental monitoring, two settle plates (TSA and SDC) were exposed during each handling near the activity for a maximum of 4 h. For staff monitoring, when work shift finished, the operator gloves print (5 fingers) were monitored in each media (TSA and SDC).

6. Analytical method validation

Analytical methods of sterility, mycoplasma and endotoxin are “limit tests” analytical procedures, for this, an investigation of specificity; limit of detection (LOD) should be conducted during their validation according to ICH Q2 (26). In the development phase of an analytical procedure, robustness should also be considered GMP (27).

The validation of sterility test was carried out in the intermediate product (cells with expansion medium) and in the final cellular medicine (cells and packaging medium),
each in triplicate. (Aquí define los productos “intermediate and final” sin embargo no lo especificas en los apartados anteriores).

Validation detection of mycoplasma and endotoxin assay was carried out with three samples of intermediate product (phase of MCB) of each culture (1, 2 and 3).

6.1. Validation of sterility test.

Validation was carried out to verify if the antimicrobial activity of the intermediate product and final cellular medicine had been satisfactorily eliminated under the conditions of the test (18, 19). Specificity for sterility test was analyzed by absence of false positive results (28), to determine LOD, a visual evaluation of turbidity was performed (18) and the robustness of these methods was studied by the reproducibility of the procedures.

The test was validated with respect to LOD accepted by Pharmacopoeia, with an inoculum not more than 100 cfu (BioBall SingleShot - bioMérieux, France). BioBall is an accredited reference material which contains a precise number of between 28 and 30 cfu with a standard deviation of 3 cfu (18). The validation was based on the inoculation, in a laminar flow cabinet BIOII-A (Telstar S.A., Madrid, Spain), of six different viable microorganisms, in each medium (TSB and TSPB) with 1 mL of supernatant and of final suspension. The microorganisms used for the validation are indicated in Table I.

All media were incubated for 3 days for bacteria (Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus and Bacillus subtilis) and 5 days for fungi (Aspegillus niger and Candida albicans) at 35 °C and 22 °C for TPB and TSPB, respectively. For each microorganism a Gram stain was performed at the end of
incubation to confirm microorganism identity as well as a growth promotion test as a positive control.

6.2. Validation of mycoplasma detection test

Demonstration of specificity requires the use of a suitable range of bacterial species other than mycoplasmas. Bacterial genera with close phylogenetic relation to mycoplasmas are most appropriate for this validation, e.g. *Lactobacillus* (21). To determine the LOD for mycoplasma assay, the performance and reproducibility of the analytical procedure with a reference strain known as *Mycoplasma orale* (*NCTC 10112*) (29) was demonstrated. The LOD studied was 10 cfu/mL of *M. orale* (21).

Each sample (5 × 10⁵ cells by 500 µL of supernatant) was inoculated by *M. orale* with a final concentration of 10 cfu/mL. *M. orale* reference strain was obtained from European Directorate for the Quality of Medicines (EDQM). Briefly, in the inoculated samples, the mycoplasma assay was carried out 8 times for each sample in the same PCR assay. This procedure was repeated three times on different days to analyze the variability and robustness (30).

6.3. Validation of endotoxin assay

To validate the analytical procedure used for endotoxin assay, two studies were conducted: confirmation of the labelled lysate sensitivity and test for interfering factors. Specificity was demonstrated by the absence of interfering factors, for determining of LOD, a visual evaluation of the gelation was performed with a lysate sensitivity of 0.03 EU/mL and the robustness was studied by the reproducibility (23).

6.3.1. Confirmation of the labelled lysate sensitivity
This study was performed in three different batches of LAL to confirm the labelled lysate sensitivity ($\lambda$), which must be 0.03 EU/mL (23). $\lambda$ was the antilog$_{10}$ of this mean log endpoint (the last positive result in the series of endotoxin decreasing concentration).

For each batch, 4 endotoxin standard dilutions were used ($2\, \lambda$, $1\, \lambda$, $0.5\, \lambda$ and $0.25\, \lambda$). In a pyrogen-free tube with 100 $\mu$L of LAL, 100 $\mu$L of each standard dilution were added. Each dilution was assayed in quadruplicate. All tubes were incubated at 37 ºC for 1 h in water bath. Then, the presence/absence of gelation in each tube was observed, and the endpoints were determined. Each endpoint was converted to log$_{10}$ and the mean and the antilog$_{10}$ were calculated.

6.3.2. Test for interfering factors

This study was performed in three samples of intermediate product (phase of MCB) to check the presence of interfering factors. Test solution was used at a dilution 1:10 (less than the MVD). Four solutions were necessary named A, B, C and D. Solution A (4 replicates of test solution) was the diluted sample in water for BET (1:10). Solution B (B consisted of 4 replicates of each concentrations equivalent to $2\, \lambda$, $\lambda$, $0.5\, \lambda$ and $0.25\, \lambda$ by diluting the standard endotoxin with test solution) was prepared concentrations of $2\, \lambda$, $1\, \lambda$, $0.5\, \lambda$ and $0.25\, \lambda$. $2\, \lambda$ was elaborated with 100 $\mu$L standard solution of $20\, \lambda$ and 900 $\mu$L of diluted sample. $1\, \lambda$ was manufactured with 100 $\mu$L solution of $2\, \lambda$ and 100 $\mu$L of diluted sample. $0.5\, \lambda$ was made up with 100 $\mu$L solution of $\lambda$ and 100 $\mu$L of diluted sample. $0.25\, \lambda$ was produced with 100 $\mu$L solution of $0.5\, \lambda$ and 100 $\mu$L of diluted sample. Solution C (2 replicates of each concentrations equivalent to $2\, \lambda$, $\lambda$, $0.5\, \lambda$ and $0.25\, \lambda$ by diluting the standard endotoxin with water for BET) was standard.
concentrations of 2 λ, 1 λ, 0.5 λ and 0.25 λ. Solution D (2 replicates of water for BET) was the water for BET.

In a pyrogen-free tube 100 µL of each solution (A, B, C, D) was added with 100 µL of LAL. All tubes were incubated at 37 ºC for 1 h in water bath. Solution A and B were assayed in quadruplicate and solution C and D in duplicate. Then the presence/absence of gelation was observed.

Results

1. Isolation and culture of MSCs

Three different cultures (named: 1, 2 and 3) of MSCs from human adipose tissue were analyzed according to the QCP proposed, as shown in Figure 1, for the manufacturing of a cellular medicine under GMP conditions. Three samples of adipose tissue were processed to carry out the ex vivo expansion. For each biological tissue sample a serological report was required. The results of the three samples were negative for Immunoglobulin M (IgM) A hepatitis, surface B Antigen, IgG C hepatitis and HIV; and positive for Anti HBc and Anti HBs. All materials and reagents necessary for the elaboration of the hMSCs were controlled, their sterility was analyzed and all results were negative, no microbiological growth was shown in any media (TSB and TSPB). Also, the endotoxin assay was performed and the results demonstrated that all materials and reagents were endotoxin free.

For ex vivo expansion, different critical points have been defined: MCB, WCB and final cellular medicine, in each point the analytic techniques required to ensure the microbiological quality of the culture were proposed. Throughout the process a qualitative and quantitative environmental analysis of microbiological quality of air and
surfaces were carried out, the results were within the standards required by the GMP guidelines as previously described (25).

2. **Sterility test and Gram stain.**

Before carrying out the sterility test of samples, the effectiveness of two isolation media (TSB and TPSB) was demonstrated by growth promotion test with reference strains (*Clostridium sporogenes, Pseudomonas aeruginosa, Staphylococcus aureus, Aspergillus niger, Bacillus subtilis and Candida albicans*). Turbidity was observed in all media. On the other hand, sterility test of each medium was also satisfactory. After verification of the culture media, they were inoculated with the test sample of the different phases and, after 14 days incubation, none showed turbidity, so there was no evidence of microbial growth and the sterility of the cells was accepted for the three cultures. All negative control samples with NaCl were negative after the required incubation period.

From the results of Gram stains no cfu were observed, in none of the three final cellular medicines studied.

3. **Detection of mycoplasma**

The presence of mycoplasma in each sample was analyzed by DNA amplification and the presence of 267 bp amplicon, none of the samples of the different phases showed presence of this band (data not shown). A successful PCR was performed without polymerase inhibition. Internal Control DNA was demonstrated by a 191 bp band in the gel, which verified extraction, reverse transcription, amplification, detection carried out since the internal control was added to the sample before isolating the nucleic acid.
4. Endotoxin assay

The threshold of endotoxin was calculated using the formula Endotoxin Limit (EL) = K/M (27). Where K is the threshold pyrogenic dose of endotoxin per kilogram of body mass in one hour period and M is the maximum recommended dose of the product per kilogram of body mass in one hour period. For intravenous administration, the suggested value of K by the EP is 5.0 EU/kg · h and M was 1 mL/kg · h for the final cellular medicine manufactured in our laboratory, thus:

\[ \text{EU} = \left( \frac{5.0 \text{ EU/kg} \cdot \text{h}}{1 \text{ mL/kg} \cdot \text{h}} \right) \]

\[ \text{EU} = 5.0 \text{ EU/mL} \]

The threshold of endotoxin was defined for each sample as 5.0 EU/mL.

LAL used for the endotoxin assay had a sensibility of 0.03 EU/mL, which is lower than EL calculated in-house: 5.0 EU/mL, thereby, preventing false negatives.

For the preparation of sample, MVD was calculated according to the formula:

\[ \text{MVD} = \frac{\text{EL}}{\lambda} = \frac{5 \text{ EU/mL}}{0.03 \text{ EU/mL}} = 166.7 \]

The sample could be diluted 166.7 times; in our method the selected dilution was 1:10, far below the permitted MVD. In each phase for ex vivo expansion, diluted samples were tested and including negative control no sample showed gelation except the two positive controls.

In addition, a study of storage stability was performed; the concentration selected for this study (0.08 EU/mL) was based on the preparation of a concentration similar to positive control. The positive control was calculated according to the formula:

\[ 2 \lambda = 2 \times 0.03 \text{ EU/mL} \]

The positive control was 0.06 EU/mL. All samples showed gelation except the negative control samples for the duration of the study (6 months) at 4 ºC and −20 ºC. The gelation demonstrated the presence of endotoxin from E. coli. And therefore, the storage
conditions of a sample in a QCP defined for endotoxin assay were at 4 °C or −20 °C for a maximum of 6 months.

5. Microbiological monitoring in process

Results were interpreted according to the annex I-GMP, (Grade A: < 1 cfu/4 h and < 1 cfu/glove, for environmental and staff monitoring respectively) (31).

The effectiveness of the aseptic procedures has to be continuously evaluated in order to guarantee the safety of the medicine and to identify foci of contamination risk. The results obtained for environmental and staff monitoring during the ex vivo expansion of the three cultures were within the recommended specifications for microbial contamination in TSA and SDC.

6. Validation of the analytical method

Analytical methods described in pharmacopoeia monographs are considered validated; however, the laboratory must also confirm the procedure in-house with the samples for study in each technique initially, ensuring that there is no interference.

6.1. Validation of sterility test.

No antimicrobial activity was observed in the three cultures studied of any of the microorganisms tested. The media inoculated with the supernatant and the microorganisms presented a similar growth as in the promotion test, proving that the antibiotic present in the product does not interfere with the results of the sterility test. Gram stains of these media inoculated evidenced the microorganisms added.

In the study of cell culture sterility, the presence of antibiotic in the expansion medium as microbial growth inhibitory substance must be taken into account. The antibiotic
concentration in 1 mL of supernatant was 100 UI/mL of penicillin G and 0.01 mg/mL of streptomycin, and was inactivated with $10^3$ UI/mL of penicillinase contained in the medium (TPB and TPSB).

Absence of false positive results confirmed the specificity of the test. The LOD was shown because all the microorganisms were grown at a concentration of 30 cfu/125 mL. The robustness was demonstrated satisfactorily by three replicates testing.

6.2. Validation of mycoplasma detection

The studied specificity by the kit manufacturer did not detect any of the phylogenetically related microorganisms, *Clostridium*, *Lactobacillus* and *Streptococcus*. To evaluate LOD, *M. orale* was selected in terms of the most possible source of contamination. The required LOD of 10 cfu/mL was reached in all conditions (n=24 results: eight test replicates for each of the three samples) using different combinations of different reagents and reagent lots at different working dates by different analysts (Figure 2). On different days and with different samples, the same results were obtained; *M. orale* was detected with equal certainty. The results presented demonstrate the robustness of mycoplasma PCR-based test.

6.3. Validation of endotoxin assay

6.3.1. Confirmation of labelled lysate sensitivity

Three batches of Pyrogent Ultra Gel Clot with labelled sensitivity of 0.03 EU/mL were evaluated with standard solutions. The standard solutions potency had been previously established using the current FDA Reference Standard Endotoxin. The results of these studies are described in Table II. The results from this study confirmed the $\lambda$. The
sensitivities measured were not less than 0.5 \( \lambda \) (0.015 EU/mL) and not more than 2 \( \lambda \) (0.06 EU/mL).

6.3.2. Test for interfering factors

The results of the assay are showed in Table III. Solution A was negative for three samples, which indicated no detectable endotoxin. The sensitivity was determined with solution B in the three cultures, which was not less than 0.5 \( \lambda \) (0.015 EU/mL) and not greater than 2 \( \lambda \) (0.06 EU/mL). The test solution did not contain interfering factors under the experimental conditions used. The sensitivity of the LAL was confirmed with solution C, and the negative control (solution D), was confirmed.

For endotoxin test absence of interfering factors validated the specificity. The LOD was confirmed for an amoebocyte lysate sensitivity of 0.03 EU/mL and the robustness was demonstrated by three times satisfactory testing. The three analytical procedures (sterility, mycoplasma and endotoxin) satisfied the required characteristics for a limit test: specificity, LOD and robustness as shown in Table IV.

**Discussion**

The quality of any pharmaceutical product, including biological medicines as a CTMP, is established by the European Medicine Agency guidelines in conjunction with GMP guidelines and general chapters of the EP. In addition, each laboratory should establish a quality system tailored to their own process and the characteristic of the cellular medicine they are producing.

Medicines are generally subjected to end-product batch testing as a means of quality control; in the case of a biologic medicine using stem cell, for clinical use, this control
must be amplified due to limitations inherent in the cells, such as viability, genetic stability related to extended culture time and microbiological contamination (32, 33). Microbiological contamination is one of the major risks associated with the administration of a CTMP. Therefore, it will be necessary to establish minimum standards of microbiological quality during the manufacture of these medicines through a QCP as proposed in this paper, encompassing microbiological analysis of biological sample, materials, reagents, intermediate and final product, as well as the environmental microbiological quality of air, surfaces and staff (34).

In this study, our results showed no microbiological contamination in any of the phases of cultures studied according to the QCP. In each of the three cultures studied, quality of adipose tissue sample was analyzed based on their serology and the existence of cellular pathogens and exogenous contaminants after the process of *ex vivo* expansion. Furthermore, all starting materials and reagents involved in the expansion process were tested for sterility and endotoxin and their traceability was followed (33, 35).

A CTMP must be viable for its administration, besides being sterile (36, 37). So that the manufacture of these medicines should be carried out under aseptic conditions, in a clean room and under GMP conditions, preventing contamination of the medicine and ensuring its quality, which requires identifying and controlling the critical aspects of *ex vivo* expansion (38).

A sterility test may be defined as a critical, the traditional method described in EP (18, 38) for the sterility test takes 14 days, although other rapid methods have been published and supported in the last annex II of the GMP (39), which entail 7 days (40), however the “shelf-lives” of cells do not exceed 48 h. Therefore, the final cell medicine must be released parametrically (41), being necessary to provide all additional quality controls described in QCP to ensure that the medicine is free of contaminating
microorganisms at the time of release (42). Through sterility tests prior to release, in the intermediate phases (MCB and WCB) and on the starting material and reagents, besides endotoxin and mycoplasma assays, Gram stain and management of the monitorization process in the final cellular medicine, the absence of viable and actively microorganisms can be ensured (9).

Regarding the contamination risk of a biologic medicine, mycoplasma contamination is a major problem (43, 44). It can produce a myriad of different effects with a dramatic alteration of biological characteristics of the contaminated cells: alteration of proliferation characteristics, immune reactions, viruses’ proliferation, chromosomal aberrations, and more besides. These organisms are resistant to most antibiotics commonly employed in cell cultures (19), therefore, it is essential to analyze both the intermediate products and the final medicine in the development of a CTMP to control disturbances not only to the cells, but also to the inhibition of cell growth and hence the difficulty to obtain the final dose. Although the incidence of mycoplasma infection in the cultures is low (45), in most cases having a human origin, making staff the major source of contamination, particularly Mycoplasma orale. Accordingly, staff should receive regular training for the aseptic manipulation of therapeutics (25). Also, both animal serum products and environment are possible sources of contamination (46).

Endotoxin assay is another requirement for parenteral medicines. The endotoxin effects are different depending on the cell types. It can induce contractile dysfunction, and increased production of immunoglobulin light chains. Equally, the absence of bacterial endotoxins in a product implies the absence of pyrogenic components.

We performed three successful validation runs to demonstrate the sensitivity, LOD and robustness of the method through the analytical technique validation (47). The validation parameters of different assays involved in the proposed QCP (sterility,
mycoplasma and endotoxin) demonstrated that the reagents used in each analytical technique were free of inhibitory factors and verified the suitability of each assay (48), based on the presence or absence of a detected analyte (49) by turbidity appearance, gelation after incubation, and/or detection of mycoplasma as band from PCR amplification.

In conclusion, this work proposes a control plan to analyze the safety of hMSCs as cellular medicine for clinical use, based on the evaluation of bacteriological agent contamination throughout the manufacture process.

The efficiency of the proposed QCP in this paper, carried out during the ex vivo expansion of three different cultures of hMSCs for the elaboration of autologous cell medicine under GMP conditions, has been premised on the standardization and validation in situ of each analytical technique, to ensure that the products are manufactured in a reliable and safe manner. Minimum controls of microbiological quality of the cells to be administered parenterally to patients have been established, encompassing both control samples and starting, intermediate and final material or products. Based on the QCP proposed, it was observed that the contamination risk could be prevented.

Acknowledgments

This study was supported by the Fundación Progreso y Salud, Consejería de Salud, Junta de Andalucía (Grant PI-0022/2008); Consejería de Innovación Ciencia y Empresa, Junta de Andalucía (Grant CTS-6505; INP-2011-1615-900000); FEDER co-funded grants from Instituto de Salud Carlos III (Red TerCel-Grant RD06/0010/0025; PI10/00964 and PI10/00871) and the Ministry of Health and Consumer Affairs (Advanced Therapies Program Grant TRA-120). Support from FSED and FAID allow
access to databanks. CIBERDEM is an initiative of the Instituto de Salud Carlos III.

Disclosure of interest

The authors indicate no potential conflicts of interest.

References


**Legends of Figures and Tables**

Figure 1. Scheme of manufacturing process of autologous stem cell mesenchymal as a cell therapy medicinal product.

Figure 2. Detection of PCR products by gel electrophoresis of 1 mL sample with 10 cfu *Mycoplasma orale*. Lane 1: negative control; Lanes 3 – 10: replicates 1–8 (10 cfu/mL); Lane 11: positive control; Lane 13: size marker 50 bp. The presence of mycoplasma in the sample was indicated by an amplification product at approximately 267 bp. A successfully performed PCR without polymerase inhibition was indicated by a 191 bp band (Internal Control DNA). Three individual sample batches were tested with 8 replicates for each one. On different days the same results were obtained, *Mycoplasma orale* was detected with equal certainty. The Detection Limit (10cfu/mL) was confirmed.

Table I. Microbial strains need to the Growth Promotion Test and the Validation of Sterility Test

Table II. Results of calculated lysate sensitivity (LAL)

Table III. Results test interfering factors

Table IV. Characteristics evaluated for the test validation according to ICH Q2
Tables

Table I. Microbial strains need to the Growth Promotion Test and the Validation of Sterility Test

<table>
<thead>
<tr>
<th>Culture medium</th>
<th>Microorganisms</th>
<th>Strain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thioglycollate Penase Broth</td>
<td><em>Clostridium sporogenes</em></td>
<td>ATCC 11437</td>
</tr>
<tr>
<td></td>
<td><em>Pseudomonas aeruginosa</em></td>
<td>ATCC 9027</td>
</tr>
<tr>
<td></td>
<td><em>Staphylococcus aureus</em></td>
<td>ATCC 6538</td>
</tr>
<tr>
<td></td>
<td><em>Aspegillus niger</em></td>
<td>ATCC 16404</td>
</tr>
<tr>
<td>Tryptic Soy Penase Broth</td>
<td><em>Bacillus subtilis</em></td>
<td>ATCC 6633</td>
</tr>
<tr>
<td></td>
<td><em>Candida albicans</em></td>
<td>ATCC 10231</td>
</tr>
</tbody>
</table>

ATCC: American Type Culture Collection.
Table II. Results of calculated lysate sensitivity (LAL)

<table>
<thead>
<tr>
<th>BATCH OF LAL</th>
<th>Endotoxin standard dilution (EU/mL)</th>
<th>Endpoint EU/mL</th>
<th>Log_{10} Endpoint</th>
<th>Mean</th>
<th>Antilog_{10} Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.06 0.03 0.015 0.0075</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>+ + − −</td>
<td>0.03</td>
<td>−1.52</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td>−1.29 0.05</td>
</tr>
<tr>
<td></td>
<td>+ + − −</td>
<td>0.03</td>
<td>−1.52</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td>−1.37 0.04</td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>+ + − −</td>
<td>0.03</td>
<td>−1.52</td>
<td></td>
<td>−1.29 0.05</td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+ − − −</td>
<td>0.06</td>
<td>−1.22</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>